YWYangyang Wei

Yangyang Wei

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yangyang Wei has a total of 42 co-authors. Here are the top co-authors by number of shared publications:

  • Junyu Xiao

    Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, China

    2 shared publications
  • Ayijiang Yisimayi

    Beijing Advanced Innovation Center for Genomics (ICG), Peking University, Beijing, China

    1 shared publication
  • Bai Lu

    School of Pharmaceutical Sciences, IDG/McGovern Institute for Brain Research, Tsinghua University, Beijing, China

    1 shared publication
  • Bin Su

    Beijing Youan Hospital, Capital Medical University, Beijing, China

    1 shared publication
  • Cheng-Feng Qin

    State Key Laboratory of Pathogen and Biosecurity Academy of Military Medical Sciences Beijing China

    1 shared publication
  • Chih-Chen Wang

    National Laboratory of Biomacromolecules, Chinese Academy of Sciences (CAS) Center for Excellence in Biomacromolecules, Institute of Biophysics, CAS, Beijing 100101, China

    1 shared publication

Latest Publications

  • Proteolytic processing of secretory pathway kinase Fam20C by site-1 protease promotes biomineralization

    by Xinxin Chen, Jianchao Zhang, Pulan Liu, Yangyang Wei, Xi’e Wang, Junyu Xiao, Chih-Chen Wang, Lei Wang

    Significance: Fam20C is the bona fide “Golgi casein kinase” and generates the majority of the secreted phosphoproteome. Loss-of-function FAM20C mutations cause a type of lethal osteosclerotic bone dysplasia called Raine syndrome. In this study, we find that Fam20C resides in the Golgi apparatus as a transmembrane protein. Site-1 protease, a key regulator of cholesterol homeostasis, cleaves the Fam20C propeptide and promotes its secretion and activation. This proteolytic processing of Fam20C is critical for osteoblast differentiation and mineralization. Our results have important implications for both secretory pathway kinase regulation and biomineralization regulation.


  • Open Access

    Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines

    by Yunlong Cao, Ayijiang Yisimayi, Yali Bai, Weijin Huang, Xiaofeng Li, Zhiying Zhang, Tianjiao Yuan, Ran An, Jing Wang, Tianhe Xiao, et al.

    SARS-CoV-2 variants could induce immune escape by mutations on the receptor-binding domain (RBD) and N-terminal domain (NTD). Here we report the humoral immune response to circulating SARS-CoV-2 variants, such as 501Y.V2 (B.1.351), of the plasma and neutralizing antibodies (NAbs) elicited by CoronaVac (inactivated vaccine), ZF2001 (RBD-subunit vaccine) and natural infection. Among 86 potent NAbs identified by high-throughput single-cell VDJ sequencing of peripheral blood mononuclear cells from vaccinees and convalescents, near half anti-RBD NAbs showed major neutralization reductions against the K417N/E484K/N501Y mutation combination, with E484K being the dominant cause. VH3-53/VH3-66 recurrent antibodies respond differently to RBD variants, and K417N compromises the majority of neutralizing activity through reduced polar contacts with complementarity determining regions. In contrast, the 242–244 deletion (242–244Δ) would abolish most neutralization activity of anti-NTD NAbs by interrupting the conformation of NTD antigenic supersite, indicating a much less diversity of anti-NTD NAbs than anti-RBD NAbs. Plasma of convalescents and CoronaVac vaccinees displayed comparable neutralization reductions against pseudo- and authentic 501Y.V2 variants, mainly caused by E484K/N501Y and 242–244Δ, with the effects being additive. Importantly, RBD-subunit vaccinees exhibit markedly higher tolerance to 501Y.V2 than convalescents, since the elicited anti-RBD NAbs display a high diversity and are unaffected by NTD mutations. Moreover, an extended gap between the third and second doses of ZF2001 leads to better neutralizing activity and tolerance to 501Y.V2 than the standard three-dose administration. Together, these results suggest that the deployment of RBD-vaccines, through a third-dose boost, may be ideal for combating SARS-CoV-2 variants when necessary, especially for those carrying mutations that disrupt the NTD supersite.